Avanos Medical, Inc.
AVNS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1.6% | 4.5% | -6.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 45.6% | 52.6% | 53.6% | 55.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 7.4% | 4.2% | 4.4% | 7% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -0.8% | -43.9% | 3.9% | -221.2% |
| EPS | -0.03 | -1.66 | 0.14 | -8.64 |
| % Growth | 98.2% | -1,285.7% | 101.6% | – |
| EPS Diluted | -0.03 | -1.66 | 0.14 | -8.64 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | $0 | -$0 |
| % Margin | 5.6% | -36.5% | 12.8% | -226.4% |